Nature Biotechnology 24, 509 - 515 (2006)
doi:10.1038/nbt0506-509
Gold in the ivory tower: equity rewards of outlicensingMark Edwards1, Fiona Murray2
& Robert Yu11
Mark Edwards is managing director and Robert Yu is an analyst at Recombinant Capital, 2033 North Main Street, Walnut Creek, California 94596, USA. medwards@recap.com
2
Fiona Murray is at the MIT Sloan School of Management and the Harvard-MIT Division of Health Sciences & Technology, 50 Memorial Drive E52-567, Cambridge, Massachusetts 02142, USA. An analysis of life-science initial public offerings from three time periods reveals that the equity share received by universities and their academic researchers has changed over time.
|
